Home > Insider Trading > Filing (0001144204-15-034844)

Filing Details

Accession Number:: 0001144204-15-034844
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-06-01 16:26:36
Reporting Period:: 2015-05-28

Filing Date:: 2015-06-01
Accepted Time:: 2015-06-01 16:26:36
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1410098	Cormedix Inc.	CRMD	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1313149	W Steven Lefkowitz	C/O Cormedix Inc. 745 Route 202-206, Suite 303 Bridgewater NJ US 08807		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value Per Share	Disposition	2015-05-28	10,000	$6.16	146,471	No	4	S	Direct
Common Stock, $0.001 Par Value Per Share	Disposition	2015-06-01	29,072	$6.66	117,399	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value Per Share	174,741	Indirect	Wade Capital Corporation Money Purchase Plan
Common Stock, $0.001 Par Value Per Share	10,000	Indirect	Reporting Person's Wife

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock, $0.001 Par Value Per Share	Stock Option (right to buy)	$2.02		2024-01-09	200,000	200,000	Direct
Common Stock, $0.001 Par Value Per Share	Stock Option (right to buy)	$2.02		2024-01-09	30,000	30,000	Direct
Common Stock, $0.001 Par Value Per Share	Swries C-3 Non-Voting Convertible Preferred Stock	$1.00			45,000	4,500	Direct
Common Stock, $0.001 Par Value Per Share	Warrant (right to purchase Common Stock)	$0.90	2015-01-08	2020-01-08	22,500	22,500	Direct
Common Stock, $0.001 Par Value Per Share	Series C-3 Non-Voting Convertible Preferred Stock	$1.00			30,000	3,000	Indirect
Common Stock, $0.001 Par Value Per Share	Warrant (right to purchase Common Stock)	$0.90	2015-01-08	2020-01-08	15,000	15,000	Indirect
Common Stock, $0.001 Par Value Per Share	Warrant (right to purchase Common Stock)	$3.44	2012-08-20	2015-04-30	5,000	0	Direct
Common Stock, $0.001 Par Value Per Share	Stock Option (right to buy)	$0.90		2023-03-20	120,000	120,000	Direct
Common Stock, $0.001 Par Value Per Share	Stock Option (right to buy)	$0.68		2022-12-05	150,000	150,000	Direct
Common Stock, $0.001 Par Value Per Share	Stock Option (right to buy)	$0.29		2022-01-06	30,000	30,000	Direct
Common Stock, $0.001 Par Value Per Share	Stock Option (right to buy)	$1.10		2021-08-11	30,000	30,000	Direct
Common Stock, $0.001 Par Value Per Share	Warrant (right to purchase Common Stock)	$3.44		2015-04-30	19,536	0	Direct
Common Stock, $0.001 Par Value Per Share	Warrant (right to purchase Common Stock)	$3.44		2015-04-30	7,900	0	Direct
Common Stock, $0.001 Par Value Per Share	Stock Option (right to buy)	$5.62		2025-03-01	50,000	50,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2024-01-09	200,000	200,000	Direct
2024-01-09	30,000	30,000	Direct
	45,000	4,500	Direct
2020-01-08	22,500	22,500	Direct
	30,000	3,000	Indirect
2020-01-08	15,000	15,000	Indirect
2015-04-30	5,000	0	Direct
2023-03-20	120,000	120,000	Direct
2022-12-05	150,000	150,000	Direct
2022-01-06	30,000	30,000	Direct
2021-08-11	30,000	30,000	Direct
2015-04-30	19,536	0	Direct
2015-04-30	7,900	0	Direct
2025-03-01	50,000	50,000	Direct

Footnotes

The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control).
The options vested 100% on January 10, 2014.
On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The warrant exercise price was decreased from $1.25 per share to $0.90 per share effective September 15, 2014. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
These options vest quarterly over two years beginning June 13, 2013.
These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occuured on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
The options vest in full on the first anniversary of the date of grant.
The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
The warrants were issued as part of the Company's initial public offering in March 2010 and were exercisable beginning six months after the effective date of hte Company's registration statement related thereto.
The expiration date was originally 3/24/2015 and was extended to 4/30/2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices $6.15 to $6.17, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices $6.15 to $7.10, inclusive.